Inducing tolerability of adverse events increases sorafenib exposure and optimizes patient's outcome in advanced hepatocellular carcinoma-Reference-Cited by-同舟云学术

Inducing tolerability of adverse events increases sorafenib exposure and optimizes patient's outcome in advanced hepatocellular carcinoma

Published:2016-01-20 Issue:7 Volume:36 Page:1033-1042
ISSN:1478-3223
Container-title:Liver International
language:en
Short-container-title:Liver Int

Author:

Ponziani Francesca Romana¹,Bhoori Sherrie¹,Germini Alessandro¹,Bongini Marco¹,Flores Maria¹,Sposito Carlo¹,Facciorusso Antonio¹,Gasbarrini Antonio²,Mazzaferro Vincenzo¹

Affiliation:

1. Surgery, Hepatology and Hepato-Oncology Group; Istituto Nazionale Tumori (National Cancer Institute); Milan Italy

2. Internal Medicine and Gastroenterology; Catholic University; Gemelli Hospital; Rome Italy

Funder

Associazione Italiana per la Ricerca sul Cancro

Italian National Ministry of Health within the Hepato-Oncology Project

National Cancer Institute of Milan

Publisher

Wiley

Subject

Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/liv.13052/fullpdf

Reference25 articles.

1. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma;European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer;J Hepatol,2012

2. Management of hepatocellular carcinoma: an update;Bruix;Hepatology,2011

3. Sorafenib in advanced hepatocellular carcinoma;Llovet;N Engl J Med,2008

4. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy;Iavarone;Hepatology,2011

5. Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib;Reig;J Hepatol,2014

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sorafenib for 9,923 Patients with Hepatocellular Carcinoma: An Analysis from National Health Insurance Claim Data in South Korea;Gut and Liver;2023-06-19

2. Role of Etiology in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Counterfactual Event-Based Mediation Analysis;Cancers;2023-01-06

4. Non-Invasive Biomarkers for Immunotherapy in Patients with Hepatocellular Carcinoma: Current Knowledge and Future Perspectives;Cancers;2022-09-23

5. Optimizing systemic therapy for advanced hepatocellular carcinoma: the key role of liver function;Digestive and Liver Disease;2022-04